**Table 1 Characteristics of the Patients at Baseline.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Study  |  POLLUXT C |  CASTORT C | NCT02252172T C | ALCYONE T C | ICARIA-MMT C | CASSIOPEIAT C |
| Number of patients | 286 283 | 251 247 | 368 369 | 350 356 | 154 153 | 543 524 |
| Median age(year) | 65 65 | 64 64 | 73 74 | 71 71 | 68 66 | 59 58 |
| ECOG‡performance status -no. (%) |  |  |  |  |  |  |
| 0 | 139(48.6)150(53.0) | NA NA | 127(34.5) 123(33.3) | 78(22.3) 99(27.8) | NA NA | 265(49)257(47) |
| 1 | NA NA | NA NA | 178(48.4)187 (50.7) | 182(52.0)173(48.6)  | NA NA | 225(41)230(42) |
| 2 | NA NA | NA NA | 63 (17.1) 59 (16.0)  | 90 (25.7) 84 (23.6)  | NA NA | 53(10) 55(10) |
| ISS§ disease stage -no. (%) |  |  |  |  |  |  |
| 1 | 137(47.9)140(49.5) | 98(39.0)96(38.9) | 98 (26.6) 103 (27.9) | 69 (19.7) 67 (18.8)  | 64 (42) 51 (33) | 204(38)228(42) |
| 2 | 93 (32.5) 86 (30.4) | 94(37.5)100(40.5)  | 163(44.3)156 (42.3) | 139(39.7)160 (44.9) | 53(34) 56 (37) | 255(47)233(43) |
| 3 | 56 (19.6) 57 (20.1) | 59(23.5) 51 (20.6) | 107(29.1)110 (29.8) | 142(40.6)129 (36.2) | 34(22) 43 (28) | 84(15) 81(15) |
| Cytogenetic profile -no. (%) |  |  |  |  |  |  |
| Standard risk | T:193/228(84.6) C: 176/211(83.4) | T:140/181(77.3) C:137/174 (78.7) | T:271/319(85.0) C:279/323 (86.4) | T:261/314(83.1) C:257/302 (85.1) | 103(67) 78(51) | T:460/542(85) C:454/540 (84) |
| High risk | T:35/228(15.4) C:35/211 (16.6) | T:41/181(22.7) C:37/174 (21.3) | T:48/319(15.0) C:44/323 (13.6) | T:53/314(16.9) C:45/302 (14.9) | 24(16) 36 (24) | T:82/542(15) C:86/540 (16) |
| Median time since initial diagnosis | 3.5yr 4.0yr | 3.87yr 3.72yr | 0.95M 0.89 M | 0.8M 0.8M | 4.46yr 4.09yr | 0.92M 0.92M |
| Median no. of previous lines of therapy  | 1 1 | 2 2 | 0 0 | 0 0 | 3 3 | 0 0 |

‡ Eastern Cooperative Oncology Group (ECOG) performance status is scored on a scale from 0 to 5, with 0 indicating no symptoms and higher scores

 indicating increasing disability

§ The International Staging System (ISS) disease stage is derived on the basis of the combination of serum β2microglobulin and albumin levels.

Higher stages indicate more advanced disease.

Abbreviation：NA, not available T, trail C, control M, month

**Table 2 Characteristics of the Patients at Baseline.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study  | KEYNOTE-183T C | KEYNOTE-185T C | NCT01478048T C | ELOQUENT-3T C | ELOQUENT-2T C |
| Number of patients | 125 124 | 151 150 | 77 75 | 60 57 | 321 325 |
| Median age(year) | 65 67 | 74 74 | 65 65 | 69 66 | 67 66 |
| ECOG‡ performance status -no. (%) |  |  |  |  |  |
| 0 | 60 (48) 60 (48) | 51 (34) 55 (37) | 38 (49) 46 (61) | NA NA | NA NA |
| 1 | 65 (52) 64 (52) | 100 (66) 92(61) | 35 (46) 23 (31) | NA NA | NA NA |
| 2 | 0 0 | 0 1 (1) | 2 (3) 6 (8) | NA NA | NA NA |
| ISS§ disease stage -no. (%) |  |  |  |  |  |
| 1 | 45 (36) 45 (36) | 38 (25) 51 (34) | 26 (34) 19 (25) |  (1 or 2)53 (88) 50 (88) | 141(44) 138 (42) |
| 2 | 46 (37) 39 (31) | 68 (45) 66 (44) | 23 (30) 20 (27) | 102(32) 105(32) |
| 3 | 33 (26) 33 (27) | 44 (29) 31 (21) | 11 (14) 16 (21) | 7 (12) 7 (12) | 66 (21) 68 (21) |
| Cytogenetic profile -no. (%) |  |  |  |  |  |
|  Standard risk | 52 (42) 71 (57) | 93 (62) 89 (59) | NA NA | NA NA | NA NA |
|  High risk | 28 (22) 17 (14)  | 24 (16) 10 (7) | NA NA | NA NA | NA NA |
| Median time since initial diagnosis | NA NA | NA NA | 45M 44M | 4.8yr 4.4yr | NA NA |
| Median no. of previous lines of therapy  | 3 3 | 0 0 | NA NA | 3 3 | 2 2 |

‡ Eastern Cooperative Oncology Group (ECOG) performance status is scored on a scale from 0 to 5, with 0 indicating no symptoms and higher

 scores indicating increasing disability.

§ The International Staging System (ISS) disease stage is derived on the basis of the combination of serum β2microglobulin and albumin

 levels. Higher stages indicate more advanced disease.

Abbreviation：NA, not available T, trail C, control M, month